Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

msh id	UK:CO:VACCITECH
symbol	VACC
name	Vaccitech plc
homepage url	https://www.vaccitech.co.uk
country	GB
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	33
crunchbase url	-
linkedin url	-
founders	-

market cap	192.73M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.15
growth cost of revenue	-
growth depreciation and amortization	-0
growth ebitda	1.02
growth ebitda ratio	1
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-0.75
growth gross profit	165.8
growth gross profit ratio	-

UK:CO:VACCITECH

Vaccitech

Last Close

4.49

06/11 21:00

Market Cap

192.73M

Beta: -

Volume Today

163.05K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	47.5M
cost of revenue	47.5M
depreciation and amortization	4.32M
ebitda	869K
ebitda ratio	0.02
eps	0.14
eps diluted	0.14
operating expenses	47.5M
operating income	-3.45M
operating income ratio	-0.08

accounts receivables	-5.83M
capital expenditure	-6.14M
cash at beginning of period	214.05M
cash at end of period	194.39M
inventory	-
working capital ttm	172.67M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-